Altrius Global Dividend ETF (NASDAQ: DIVD)

Dernières nouvelles pour Altrius Global Dividend ETF (NASDAQ:DIVD)

Altrius Global Dividend ETF

Healthcare

Industrials

Financial Services

Consumer Defensive

Energy

Basic Materials

Consumer Cyclical

Technology

Real Estate

The Fund will invest at least 90% of its net assets, plus the amount of any borrowings for investment purposes, in dividend-paying equity securities. The principal type of equity security in which the Fund will invest is common stock. The Fund invests primarily in the securities of issuers that the Sub-Adviser believes to have attractive valuations, potential for long-term growth, sustainable dividends, and other attractive financial characteristics. The Funds portfolio is composed of approximately 45 to 100 stocks (including American Depositary Receipts or ADRs). Under normal market conditions, at least 30% of the Funds assets will be invested outside the United States. The majority of the stocks normally will have market capitalizations greater than $1 billion at the time of purchase by the Fund.

Siemens Ag

British Amer Tobacco Plc

Novartis Ag, Adr

Bae Systems Plc Adr

Merck & Co Inc

Royal Bank of Canada

Abbvie Inc.

Banco Bilbao Vizcaya Argentaria Sa

Eaton Corp Plc

Amcor Plc

Cnh Industrial Nv

Air Products And Chemicals Inc.

Axa SA

Companhia De Bebidas Das Americas (Ambev) (Adr)

Scotiabank analyst Konark Gupta maintains Bombardier (TSX:<a class="ticker" href="https://www.benzinga.com/stock/BBD#TSX">BBD</a>) with a Sector Perform and lowers the price target from C$109 to C$105.

News

Price Target

Analyst Ratings

TSX:BBD

TSX:BBD/B

Scotiabank Maintains Sector Perform on Bombardier, Lowers Price Target to C$105

Stifel analyst Alex Thompson maintains Travere Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVTX#NASDAQ">TVTX</a>) with a Hold and raises the price target from $22 to $23.

TVTX

Stifel Maintains Hold on Travere Therapeutics, Raises Price Target to $23

JMP Securities analyst Andrew Boone maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Market Outperform and raises the price target from $155 to $180.

RDDT

JMP Securities Maintains Market Outperform on Reddit, Raises Price Target to $180

WIIM

ECX stock has given up its prior loss. ECARX Holdings shares were trading lower following Q1 reported financial results.

<a href="https://www.bloomberg.com/news/articles/2025-05-02/opec-brings-forward-call-to-discuss-june-output-plans-to-may-3?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-02/opec-brings-forward-call-to-discuss-june-output-plans-to-may-3?embedded-checkout=true</a>

Macro Notification

General

'OPEC+ Brings Forward Call to Discuss June Output Plans to May 3'- Bloomberg

Stifel analyst Bert Subin maintains Schneider National (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDR#NYSE">SNDR</a>) with a Hold and lowers the price target from $25 to $22.

SNDR

Stifel Maintains Hold on Schneider National, Lowers Price Target to $22

Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) shares are trading lower Friday after CEO Tim Cook said that the company expects a $900 million cost impact in the June quarter <a href="https://www.benzinga.com/tech/25/05/45156890/apple-ceo-tim-cook-warns-of-900-million-tariff-impact-in-june-quarter-expects-majority-of-iphones-sold-in-us-to-be-made-in-india">due to tariffs.</a>
The Details: Cook said during the company's <a href="https://www.benzinga.com/news/earnings/25/05/45152493/apple-reports-strong-q2-earnings-revenue-beat-eps-beat-installed-base-hits-all-time-high-across-all-segments-100-billion-buyback-and-more">quarterly earnings</a> call that, &#8220;Assuming that the current global tariff rates, policies and applications don&#8217;t change for the balance of the quarter,&#8221; the impact will be $900 million to the company&#8217;s costs.
Apple has already begun shifting iPhone production, its most profitable product, to India. Cook stated that he expects most iPhones sold in the U.S. will soon originate from India.
China has long served as the main manufacturing base for iPhones sold in the U.S. Vietnam is set to become the main production hub for nearly all iPads, Macs, Apple Watches and AirPods sold in the U.S.
Apple&#8217;s move to diversify its supply chain comes in response to President Donald Trump&#8216;s imposition of tariffs of up to 145% on Chinese imports.
See Also: <a href="https://www.benzinga.com/personal-finance/financial-advisors/25/05/45166652/dave-ramsey-tells-couple-with-300000-income-they-are-broke-people-refuses-to-help-heres-why">Dave Ramsey Tells Couple With $300,000 Income They Are &#8216;Broke People&#8217;, Refuses To Help: Here&#8217;s Why</a>
AAPL Price Action: At the time of writing, Apple shares are trading 3.79% lower at $205.23, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro.</a>
Image: via Shutterstock

Movers

AAPL

Apple Stock Falls After Cook Warns of $900M Tariff Impact

Stifel analyst Steve Wieczynski maintains Red Rock Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRR#NASDAQ">RRR</a>) with a Hold and lowers the price target from $54 to $44.

Stifel Maintains Hold on Red Rock Resorts, Lowers Price Target to $44

U.S. stocks traded higher this morning, with the S&amp;P 500 gaining over 1% on Friday.
Following the market opening Friday, the Dow traded up 0.91% to 41,121.95 while the NASDAQ climbed 1.11% to 17,906.97. The S&amp;P 500 also rose, gaining, 1.06% to 5,663.28.
Check This Out: <a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a>
Leading and Lagging Sectors Industrials shares rose by 1.6% on Friday.
In trading on Friday, energy stocks dipped by 0.3%.
Top Headline
Nonfarm payrolls increased by 177,000 last month, slightly down from a downwardly revised 185,000 in March, according to data released Friday by the Bureau of Labor Statistics.
The outcome surpassed both economist forecasts for a 130,000 gain and betting markets – tracked by CFTC-regulated platform Kalshi – which had priced in a 90,000 increase. The unemployment rate remained unchanged at 4.2%, as expected.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares shot up 286% to $0.9725. The company recently reported successful safety study of a formulation of PL-14 allergy blocker in human nasal tissue model.</li>
<li>Shares of Freight Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>)got a boost, surging 142% to $2.3750 on continued strength after the company on Thursday announced it entered into an agreement for the issuance of convertible notes through a facility of up to $20 million. Capital from the financing will be earmarked for purchasing Official Trump Tokens.</li>
<li>Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>) shares were also up, gaining 103% to $0.8122.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Pineapple Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#NYSE">PAPL</a>) shares dropped 42% to $0.1150 after the company announced a $1.5 million public offering.</li>
<li>Shares of E-Home Household Service Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) were down 42% to $0.1733.</li>
<li>Draganfly Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) was down, falling 40% to $1.77 after the company priced a $3.6M underwritten public offering at $2.10 per unit</li>
</ul>
Commodities In commodity news, oil traded down 2.5% to $57.79 while gold traded up 1% at $3,253.10.
Silver traded down 0.3% to $32.360 on Friday, while copper rose 1% to $4.6735.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1.3%, Spain's IBEX 35 Index gained 0.6% while London's FTSE 100 rose 1%. Germany's DAX 40 rose 2.1% and France's CAC 40 added 1.9% during the session.
Asia Pacific Markets
Asian markets closed higher on Friday, with Japan's Nikkei gaining 1.04%, Hong Kong's Hang Seng Index surging 1.74% and India's BSE Sensex rising 0.32%.
Economics
<ul>
<li>Nonfarm payrolls increased by 177,000 last month, slightly down from a downwardly revised 185,000 in March, according to data released Friday by the Bureau of Labor Statistics. The outcome surpassed both economist forecasts for a 130,000 gain and betting markets – tracked by CFTC-regulated platform Kalshi – which had priced in a 90,000 increase.</li>
<li>The unemployment rate remained unchanged at 4.2%, as expected.</li>
<li>New order for U.S. manufactured goods rose by 4.3% to $618.8 billion in March.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45164963/how-to-earn-500-a-month-from-tyson-foods-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Tyson Foods Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

Earnings

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

DPRO

FRGT

PAPL

PLRZ

S&P 500 Gains 1%; April Jobs Top Expectations

Stifel analyst Parker Lane maintains Pros Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRO#NYSE">PRO</a>) with a Buy and lowers the price target from $30 to $24.

Stifel Maintains Buy on Pros Holdings, Lowers Price Target to $24

Scotiabank analyst Mario Saric maintains Allied Properties REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AP#TSX">AP</a>) with a Sector Outperform and lowers the price target from C$20.5 to C$19.

TSX:AP

TSX:AP/UN

Scotiabank Maintains Sector Outperform on Allied Properties REIT, Lowers Price Target to C$19

Stifel analyst Adam Borg maintains Procore Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCOR#NYSE">PCOR</a>) with a Buy and lowers the price target from $93 to $75.

PCOR

Stifel Maintains Buy on Procore Technologies, Lowers Price Target to $75

JMP Securities analyst Reni Benjamin maintains Bicycle Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCYC#NASDAQ">BCYC</a>) with a Market Outperform and lowers the price target from $26 to $22.

BCYC

JMP Securities Maintains Market Outperform on Bicycle Therapeutics, Lowers Price Target to $22

Stifel analyst Brad Reback maintains Paylocity Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCTY#NASDAQ">PCTY</a>) with a Buy and lowers the price target from $250 to $235.

PCTY

Stifel Maintains Buy on Paylocity Holding, Lowers Price Target to $235

On Friday, AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) reported topline data from Phase 3 KALOS and LOGOS trials in patients <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">with uncontrolled asthma</a>.
KALOS and LOGOS trials assessed the efficacy and safety of Breztri Aerosphere&nbsp;(budesonide/glycopyrronium/formoterol fumarate or BGF) compared with two fixed-dose, dual-combination therapies of budesonid (an ICS) and formoterol fumarate (LABA) and&nbsp;Symbicort&nbsp;pressurized metered-dose inhaler (pMDI).
KALOS and LOGOS included approximately 4,400 randomized patients.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44083934/amgen-astrazeneca-partnered-asthma-drug-shows-rapid-and-sustained-effect-in-chronic-rhinosinusitis" rel="noreferrer noopener">Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis</a>
The <a target="_blank" href="https://www.astrazeneca.com/media-centre/press-releases/2025/breztri-met-primary-endpoints-in-ph3-asthma-trials.html" rel="noreferrer noopener">trials</a> met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines.
No new safety or tolerability signals were identified for&nbsp;Breztri&nbsp;in KALOS or LOGOS.
Full results from the two Phase 3 trials will be shared with regulatory authorities and presented at an upcoming medical meeting.
Breztri&nbsp;is an inhaled triple-combination therapy approved for chronic obstructive pulmonary disease (COPD) in adults in more than 80 countries worldwide, including the US, EU, China, and Japan.
In addition to the two registrational trials (KALOS and LOGOS),&nbsp;two qualifying trials, LITHOS and VATHOS, also met their primary endpoints. LITHOS and VATHOS included approximately 1,000 randomized patients.
In April, Sanofi SA&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) reported&nbsp;preliminary results from the TIDE-Asthma phase 2 study of amlitelimab and its efficacy in <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44822758/sanofi-asthma-drug-misses-primary-goal-plans-for-pivotal-study" rel="noreferrer noopener">heterogeneous inflammatory asthma</a>.
<ul>
<li>The primary endpoint of the annualized exacerbation rate at week 48 was not met at the highest dose level, leading to nominal significance at the medium and low doses.</li>
<li>Treatment with amlitelimab led to nominally significant and clinically meaningful reductions in asthma exacerbations at the medium dose tested and a numerically greater reduction in exacerbations at the high dose at week 60.</li>
<li>A nominally significant and clinically meaningful improvement in secondary endpoints of lung function and asthma control was evident.</li>
<li>In a patient subgroup, amlitelimab showed nominally significant and clinically meaningful improvements in exacerbations (with a reduction of more than 70%), lung function, and asthma control at week 60.</li>
</ul>
AstraZeneca announced in its&nbsp;first-quarter presentation&nbsp;(PDF) on Tuesday that it had <a target="_blank" href="https://www.astrazeneca.com/content/dam/az/PDF/2025/q1/Q1-2025-results-clinical-trials-appendix.pdf" rel="noreferrer noopener">stopped</a> working on a phase 1 Alzheimer's disease drug and two phase 2 programs for migraine and osteoarthritis pain and painful diabetic neuropathy.
On Tuesday, the European pharma giant reported first-quarter 2025 sales of $13.59 billion, up 7% year over year (+10% at constant currency), slightly missing the&nbsp;consensus of $13.71 billion, driven by double-digit growth in <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/45069668/astrazeneca-q1-sales-and-earnings-rise-warns-china-import-tax-could-be-up-to-8-million-ceo-says-tariff-related-exposure-limited" rel="noreferrer noopener">oncology and biopharmaceuticals</a>.
Price Action: AZN stock is up 1.52% at $71.58&nbsp;at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/05/45165804/cigna-ceo-says-strong-q1-earnings-increased-outlook-reflect-strength-in-growth-platforms" target="_blank" rel="noreferrer noopener">Cigna CEO Says Strong Q1 Earnings, Increased Outlook Reflect Strength In Growth Platforms</a></li>
</ul>
Photo by Piotr Swat Shutterstock

Biotech

Large Cap

Health Care

AstraZeneca's Triple-Combination Therapy Breztri Hits Primary Goals In Two Pivotal Studies For Asthma

Scotiabank analyst Robert Hope maintains AltaGas (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ALA#TSX">ALA</a>) with a Sector Outperform and raises the price target from C$42 to C$45.

TSX:ALA

Scotiabank Maintains Sector Outperform on AltaGas, Raises Price Target to C$45

Stifel analyst Nathan Jones maintains Parker Hannifin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PH#NYSE">PH</a>) with a Hold and raises the price target from $564 to $630.

Stifel Maintains Hold on Parker Hannifin, Raises Price Target to $630

<a href="https://punchbowl.news/wp-content/uploads/EMBARGOED-President-Trumps-Fiscal-Year-2026-Discretionary-Funding-Request-Overview.pdf">https://punchbowl.news/wp-content/uploads/EMBARGOED-President-Trumps-Fiscal-Year-2026-Discretionary-Funding-Request-Overview.pdf</a>
&nbsp;

Government

Regulations

President Trump's Fiscal Year 2026 Budget Increases Defense Spending By 13%; Increases Homeland Security Spending By 65%; Reduces Non-Defense Spending By 23%

Scotiabank analyst Greg Harrison maintains Agios Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGIO#NASDAQ">AGIO</a>) with a Sector Outperform and lowers the price target from $74 to $71.

AGIO

Scotiabank Maintains Sector Outperform on Agios Pharmaceuticals, Lowers Price Target to $71

JMP Securities analyst Nicholas Jones maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Market Outperform and raises the price target from $240 to $250.

Comments

Altrius Global Dividend ETF

Actualités

Dernières nouvelles pour Altrius Global Dividend ETF (NASDAQ:DIVD)

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL